Pride festivals across Europe are facing the prospect of cancellation due to the threats posed by the coronavirus pandemic.
US: LGBTQ People Especially at Risk for COVID-19, Say 100+ Organizations
US: More than 100 colleges cancel in-person classes and move online
US: Harvard gives students 5 days to evacuate over coronavirus fears—here’s what students have to say
Canada: Federal Liberals introduce bill aimed at cracking down on conversion therapy
South Africa: Community-based HIV treatment superior to clinic-based care for men
New high-cost HIV prevention drug: 'Better' isn't worth it
A newly approved drug for HIV pre-exposure prophylaxis (PrEP) is unlikely to confer any discernible health benefit over generic alternatives and may undermine efforts to expand access to HIV prevention for the nation's most vulnerable populations, according to a new study appearing today in the Annals of Internal Medicine.
US: CROI Goes Digital After COVID-19 Cases Rise in Boston
Australia: Submissions to the ‘Religious Freedom’ bill released
Australia: Physicians college calls for increased access to transgender treatment
One-third of patients taking PrEP in Kenya, Uganda demonstrate poor adherence
One-third of patients at an elevated risk for HIV who initiated pre-exposure prophylaxis, or PrEP, in Kenya and Uganda had drug concentrations in hair samples that were consistent with poor adherence, suggesting a need for new approaches and long-acting formulations of this agent, according to a study published in Lancet HIV.